To identify targets for novel anabolic medicines for osteoporosis, we recruited a large cohort with unexplained high bone mass (HBM). Exome sequencing identified a rare (minor allele frequency 0.0014) missense mutation in SMAD9 (c.65T>C, p.Leu22Pro) segregating with HBM in an autosomal dominant family. The same mutation was identified in another two unrelated individuals with HBM. In-silico protein modelling predicts the mutation severely disrupts the MH1 DNA-binding domain of SMAD9. Affected individuals have bone mineral density [BMD] Z-Scores +3 to +5, with increased volumetric cortical and trabecular BMD, increased cortical thickness, and low/normal bone turnover. Fractures and nerve compressions are not seen. Both genome-wide, and gene-based association testing of heel estimated-BMD in >362,924 UK-Biobank British subjects showed strong associations with SMAD9 (PGWAS=6x10 -16 ; PGENE =8×10 -17 ). Smad9 is highly expressed in murine osteocytes and zebrafish bone tissue. Our findings support SMAD9 as a novel HBM gene, and a potential novel osteoanabolic target.
Background
Age-related bone loss with deterioration of skeletal architecture leads to osteoporosis, affecting 8.2 million women and 2.0 million men aged 50 years and older in the United States (US) 1 . Worldwide, osteoporosis causes more than 8.9 million fractures annually 1 . Osteoporotic fractures and their treatment are a major cause of morbidity and mortality, with annual US healthcare costs exceeding $20 billion 2 . Most osteoporosis treatment approaches, including all oral medications, reduce bone resorption and prevent further bone loss, rather than enhance bone formation. Affordable anabolic treatments, which can restore bone mass and skeletal architecture, are much needed.
Romosozumab, a monoclonal antibody against sclerostin, represents a new class of anti-osteoporosis drugs 3, 4 (licensing currently under review). Sclerostin, a key inhibitor of bone formation, was discovered through study of two rare syndromes of extreme high bone mass (HBM) due to mutations in SOST 5, 6 . SOST encodes Sclerostin which binds to low-density lipoprotein receptor-related proteins 5 and 6 (LRP5 and LRP6) to prevent activation of canonical WNT signalling in bone, resulting in decreased bone formation. Gain-of-function mutations in LRP5 and LRP6 can also cause extreme HBM 7, 8 . Together these sclerosing bone dysplasias are characterised by mandible enlargement with tori of the palate and mandible, bone overgrowth leading to nerve compression, a tendency to sink when swimming, and, importantly, resistance to fracture 5, 7, 9 . These important gene discoveries validate the study of rare monogenic HBM as an approach to identify novel therapeutic targets for drug development towards osteoporosis treatments.
We have previously shown that HBM (defined as a total hip and/or 1 st lumbar vertebral bone mineral density [BMD] Z-score of ≥ +3.2) is observed in 0.18% of Dual-Energy X-ray Absorptiometry (DXA) scans in the UK 10 . Most cases are unexplained, i.e. they do not carry mutations in established HBM genes 9 . Whilst such HBM populations do show enrichment for common variant associations with established BMD-associated loci 11 , we hypothesized that novel causes of monogenic HBM remain to be determined. Thus, we aimed to identify novel monogenic causes of HBM to provide insight into regulatory pathways amenable to therapeutic intervention.
Results

HBM pedigree with a segregating SMAD9 p.Leu22Pro mutation (Figure 1 and Table 1)
We investigated a pedigree with unexplained and apparently autosomal dominant HBM 9 , identified from our large UK HBM cohort 10 (Figure 1 ).
Clinical phenotype (Table 1)
Clinical phenotypes of the UK family individuals are shown in Table 1 ; extended clinical histories are provided in Supplementary Results 1. In summary, affected individuals had high BMD Z-scores, and very high body mass index (BMI); and had not have any adult fractures, nerve compression or dental problems; however, bone pain was common, without a clear cause. There was no clinical history of intellectual impairment, pulmonary hypertension, vascular hypertension, haematological abnormalities, pubertal delay or other clinical conditions. None had been exposed to anabolic or antiresorptive medications.
III.1: Index Case (c.65T>C, p.Leu22Pro)
The 33-year-old index case, with BMD Z-Scores +3.2 at the total hip and +4.5 at L1, had only sustained one traumatic fracture aged 20 months. She reported lower leg and ankle pain. She was tall (>97 th centile) and obese, with increased shoe size, a broad frame, enlarged mandible and a 4mm torus mandibularis. She had normal joints. Radiographs showed increased cortical thickness and new bone formation at the anterior inferior iliac spines bilaterally ( Supplementary Figure 1) .
II.2: Mother of the index case (c.65T>C, p.Leu22Pro)
The 55-year-old affected mother, with BMD Z-Scores +3.3 at the total hip and at L1, had never sustained a fracture. Six years earlier she had had a right calcaneal spur surgically removed. She had widespread pain with a diagnosis of fibromyalgia. She was tall (97 th centile) and obese, with above average shoe size, a broad frame, enlarged mandible but no tori. She had a full range of movement in all joints, bilateral knee crepitus and bilateral pes planus.
III.2: Half-sister to index case (c.65T>C, p.Leu22Pro)
The 22-year-old affected half-sister, with BMD Z-Scores +4.8 at the total hip and +2.6 at L1, had not fractured. She had had sciatica for five years, lumbar back pain and fronto-temporal headaches for 11 years, with a diagnosis of migraine. She was tall (93 rd centile) and obese, with above average shoe size, a broad frame, enlarged mandible, a torus palitinus in the midline of her hard palate (3cm x 7mm) and normal joint movement.
I.2: Grandmother of index case (wild-type)
The 75-years-old grandmother, who did not have HBM, had also never sustained a fracture. She had widespread osteoarthritis and on examination had reduced extension of the right elbow and left knee, and bilateral knee crepitus. However, in contrast to other family members, she was overweight with normal shoe size, a normal frame, mandible and no tori.
Sequencing of pedigree
Whole exome sequencing (WES) identified a heterozygous missense variant in SMAD9 (SMAD family Member 9 referring to homologies to the Caenorhabditis elegans SMA (small worm phenotype) and Drosophila MAD ("Mothers Against Decapentaplegic")) (NM 001127217: exon2: c.65T>C, p.Leu22Pro), segregating with HBM (i.e. present in all three individuals with HBM (III.1, II.2, III.2), but absent from I.2 (Figure 1 ). This variant (rs111748421) is rare (Exome Aggregation Consortium [ExAC] minor allele frequency [MAF] 0.0014), affects a highly evolutionarily conserved base (genomic evolutionary rate profiling [GERP] 5.53) and is predicted to be pathogenic by multiple protein-prediction algorithms (deleterious by SIFT 12 , probably damaging by Polyphen 13 , and disease causing by MutationTaster 14 and PMut 15 ).
A novel variant in CHRNA1 (cholinergic receptor, nicotinic, alpha 1) (c.560T>C, p.Leu187Pro) was also identified ( GERP 5.29). Mutations in CHRNA1 have been associated with congenital myasthenic syndromes (OMIM#100690), not present in this pedigree.
No variants were identified when applying a compound heterozygous or an autosomal recessive inheritance model.
Sequencing of other HBM cases identifies two further isolated HBM cases harbouring a p.Leu22Pro mutation
WES of a further 366 HBM cases (240 isolated cases from the UK cohort with a total hip (TH) or first lumbar vertebra (L1) Z-score ≥+3.2 and 126 individuals from the Anglo-Australasian Osteoporosis Genetics Consortium (AOGC) 16 with either a total hip and/or lumbar spine (LS) Z-score between +2.5 and +4.0) (Supplementary Figure 2 ) identified two individuals with the same SMAD9 c.65T>C, p.Leu22Pro mutation. Haplotypic analysis confirmed these women were neither related to each other nor to the pedigree described above. Figure 3; Supplementary Results 1) . This 55-year-old female, with BMD Z-Scores +5.0 at the total hip and +4.7 at L1, had never fractured and had no symptoms of nerve compression. Her adult left upper cuspid tooth had never erupted; wisdom teeth had been extracted for overcrowding. She had noticed her own mandible enlargement. She had a congenital astigmatism of her left eye with poor vision, and congenital bilateral pes planus. Height was normal (30 th centile). She was obese with a broad frame, mandible enlargement, but no tori. She had normal joints.
Clinical phenotype Isolated HBM case (c.65T>C, p.Leu22Pro) from the UK (Table 1; Supplementary
Isolated HBM case (c.65T>C, p.Leu22Pro) from Australia
This 57-year-old female, with BMD Z-Scores +3. at the total hip and +2.7 at L1, reported a nose fracture as a child. Height was on the 45 th centile and she was overweight. She did not have any history of conditions affecting bone health; and had not received antiresorptive or anabolic medications. No further clinical details were available.
Tibial pQCT evaluation
All members of the HBM pedigree, plus the additional isolated HBM case from the UK underwent pQCT scanning of the tibia ( Figure 2 ). To set these findings in context, the mean (SD) values from the four p.Leu22Pro SMAD9 HBM cases were compared against values from 76 unrelated female HBM cases (without SMAD9, LRP5, LRP4, or SOST mutations) and 32 female family controls with normal DXA-measured BMD who had had pQCT scans following the same protocol 17 . In addition to greater bone size (cross-sectional bone area) at the mid tibia (66% site), the four HBM cases with SMAD9 mutations had greater trabecular and cortical density, cortical area and thickness and predicted bone strength (strength stain index [SSI]) than other HBM cases, and, to a greater extent, than unaffected family controls (with normal DXA-measured BMD ( Table  2) ). Muscle size (cross-sectional area) was also notably larger in in the SMAD9 HBM group (Figure 2 ).
Sequencing of Low Bone Mass (LBM) cases
WES data from 473 women with LBM from the AOGC consortium with TH Z-scores between -1.5 and -4.0 and a LS Z-score ≤-0.5, obtained using similar methodology to the AOGC HBM cases, was interrogated ( Supplementary Figure 2 ). The p.Leu22Pro SMAD9 mutation was not observed.
Common SMAD9-associated genetic variants and BMD
Publicly available data from a recent population-based genome-wide association study (GWAS) of eBMD (estimated BMD by heel ultrasound in the UK-Biobank study) 18 were used to investigate variants surrounding both SMAD9 and CHRNA1. Regional association plots suggested that SNPs intersecting SMAD9 are strongly associated with eBMD (lead SNP rs12427846 [MAF 0.25], β 0.02, SE 0.002, p=5.5x10 -16 ; Figure 3 ). In contrast, SNPs surrounding CHRNA1 were not robustly associated with eBMD ( Supplementary Figure 4 ). These observations were further supported by gene-based tests of association performed in-house using 362,924 unrelated white British subjects from the UK-Biobank Study. Specifically, SMAD9 was more strongly associated with eBMD (PJOINT = 7.94 × 10 -17 ), when compared to neighbouring genes within +/-800kb (P > 2.4 × 10 -2 ) (Supplementary Table 2 ). No such enrichment was seen for CHRNA1 (Supplementary Table 3 ). Further investigation of rs12427846 in the UK-Biobank study identified weak associations with body weight (β -0.14, SE 0.04, p=1.6x10 -3 ) and with height (β -0.07, SE 0.03, p=3.5x10 -3 ) with effects in the opposite direction from that seen with eBMD; however, adjustment for weight and height did not attenuate the strong association between rs12427846 and eBMD reported above. Using PhenoScanner version 2 19 , a PheWAS for the rs12427846 variant further identified a weak association with forearm BMD with consistent direction of effect (Supplementary Table 4 ). Interrogating the GWAS Catalog (https://www.ebi.ac.uk/gwas/), no associations with any trait (neither bone-related nor any other) have been reported previously for the rare (MAF=0.0014) variant rs111748421.
Smad9 expression in murine osteocytes
We next determined whether Smad9 and Chrna1 are expressed in osteocytes, the master cell regulators in the skeleton and key regulators of bone mass 20 , and enriched in osteocytes compared to other cells in bone 21 . Smad9 mRNA was highly expressed in murine osteocytes whilst Chrna1 was not (Supplementary Table 5 ).
Smad9 expression in zebrafish skeletal tissue
We also examined Smad9 protein expression in the developing zebrafish skeleton 22 at 6-and 7-days post fertilisation (dpf) ( Figure 4A ). A focus of Smad9 expression was observed at the dorsal tip of the opercle, an intramembranous bone overlying the gills, adjacent to but distinct from a region of bone morphogenetic protein (BMP) reporter activity ( Figure 4B ). The opercula muscle group also showed evidence of BMP reporter activity, whereas Smad9 expression at this site was absent. Smad9expressing cells in the opercle were negative for the osteoblast marker, sp7 (osterix), suggesting they are likely to represent pre-osteoblasts ( Figure 4C and Supplementary video 1). Equivalent findings were observed in the branchiostegal ray bones and in the notochord at 6-and 7-dpf (Supplementary Figure 5 ).
SMAD9 protein structural modelling
SMAD9 is a TGF-beta family member DNA binding transcription factor. Phosphorylation by BMPligand-bound type 1 receptor kinase activates SMAD9, which translocates from the cytoplasm to the nucleus to regulate target gene expression 23 . The seven exons of human SMAD9 encode a protein of 467 amino acids that contains two MAD-homology (MH) domains (MAD: Mother against Dpp) separated by a linker region ( Figure 5 ). The p.Leu22Pro SMAD9 mutation is located within the MH1 domain responsible for DNA-binding ( Figure 5 ), and lies in the hydrophobic face of the N-terminal alpha helix (helix-1) ( Figure 6 , Supplementary Video 2). Helix-1 packs against a groove made by helix-2 and -3 within MH1, forming part of the hydrophobic core of this domain. Substitution of leucine by proline will: a) introduce a less hydrophobic residue into this position; and b) compromise the αhelical fold by disrupting the canonical hydrogen bonding of helix-1. Thus, modelling suggests that this mutation will disrupt the MH1 domain so severely that SMAD9 can no longer bind DNA and/or will be unstable leading to protein degradation.
Discussion
We report the first HBM pedigree with a segregating SMAD9 mutation, with replication in two further unrelated individuals with HBM. SMAD9 (also known SMAD8, MADH6, and MADH9) encodes a downstream modulator of the BMP signalling pathway. BMPs, members of the TGF-β superfamily, were first reported in 1977 to induce the formation of bone and cartilage when transplanted subcutaneously 24 . SMADs, activated by ligand-binding of cell surface BMP receptors, mediate downstream intracellular signalling and biological responses induced by BMPs 25 . Smad6 and Smad7 both inhibit BMP receptor activation and downstream signalling, as does Smad9 by more direct transcriptional repression 23 . Our in-silico protein modelling predicts that the p.Leu22Pro mutation severely disrupts the structure of the MH1 DNA binding domain of SMAD9, leading to loss of function.
Whilst few previous studies have examined sites of Smad9 tissue expression, we have confirmed that Smad9 is expressed in both mouse cortical bone derived osteocytes, and in skeletal elements of zebrafish larvae. Moreover, we observed that BMP reporter activity in zebrafish was absent at sites of Smad9 expression, consistent with a functional role in BMP repression 23 . Taken together our findings suggest that SMAD9 c.65T>C is a loss-of-function mutation, causing HBM through a novel mechanism of enhanced bone formation as a consequence of reduced BMP inhibition.
Further, we have shown that the region containing SMAD9 is strongly associated with BMD within the general population. Common variants intersecting SMAD9 associate with population-based measures of eBMD, as evidenced recently 18, 26 and from our gene-based tests of association presented here. Furthermore, rs12427846 [the lead SNP from these eBMD results] is associated with DXA-measured total body BMD 27 and fracture risk 18 . These findings, which provide further evidence of the importance of SMAD9 in bone biology, are equivalent to reported associations for common variants annotated to LRP5 and SOST genes, both similarly implicated in monogenic HBM disorders 28, 29 .
We have previously estimated unexplained HBM to have a prevalence of 0.181% amongst a DXAscanned adult population in the UK 10 . As two of 248 cases fulfilling our stringent HBM phenotype definition (Supplementary Figure 2 ) were found to harbour the p.Leu22Pro mutation, we would estimate SMAD9 HBM to have a prevalence of approximately 1 in 100,000 (1.46 x 10 -5 ); less common than LRP5 HBM 9 .
The clinical phenotype of p.Leu22Pro SMAD9 HBM includes mandible enlargement, a broad frame, torus palitinus, pes planus, increased shoe size and a tendency to sink when swimming. Adult fractures were not reported, raising the possibility of increased skeletal strength which would be supported by greater cortical bone and an increased strength-strain index (SSI) quantified by pQCT (discussed further below), both of which promote fracture resistance. Mandible enlargement, torus palitinus, a tendency to sink when swimming, and an absence of adult fractures are reminiscent of LRP5 HBM 7, 30 . Encouragingly, unlike sclerosteosis (due to anabolic SOST mutations) and some LRP5 HBM cases 9,31 , nerve compression does not seem to be a feature of SMAD9 HBM.
The musculoskeletal phenotype of p.Leu22Pro SMAD9 HBM includes high BMD Z-Scores (+3 to +5), with increased fat and lean mass. pQCT revealed that both volumetric cortical and trabecular bone density are increased. Furthermore, the larger bone size with greater cortical thickness and cortical area, suggest a possible combination of enhanced modelling to increase periosteal expansion and reduced bone remodelling to reduce endosteal expansion. In support, bone turnover markers are at the lower end of the normal range. This phenotype also mimics that previously described for human LRP5 HBM 32 . Plasma sclerostin is not elevated, in contrast to LRP5 HBM 33 , suggesting that a negative feedback loop downregulating WNT signalling is not present.
pQCT further confirmed that larger muscle size is another phenotypic feature of SMAD9 HBM, with an increase in muscle cross-sectional area. This contrasts with the suggestion from our zebrafish studies that Smad9 expression in muscle tissue may be limited. Given the well-recognised cross-talk between muscle and bone 34 and the large BMI of these individuals, it is conceivable that the increase in muscle size is a consequence of increased bone mass. However, similar increases in muscle size have not been reported in other monogenic HBM conditions (i.e. LRP5 or SOST HBM) with equivalent increases in BMD.
Heterozygous truncating SMAD9 mutations are associated with primary pulmonary hypertension (OMIM#615342) 35 , a phenotype not apparent in our HBM cases. Reported mutations affect a different domain from the mutation observed here (p.Leu22Pro), with p.Cys202X 35 and p.Arg294X 36 truncating the SMAD9 protein in the linker region between MH1 and MH2. A truncating mutation (p.Arg247X) has been associated with cerebral arteriovenous malformations in childhood 37 . An activating heterozygous p.Val90Met germline mutation, affecting the 4 th α-helix of MH1 and close to the DNA binding interface, has been described in one pedigree with hamartomatous polyposis 38 . In contrast to p.Leu22Pro, p.Val90Met appears to be a gain-of-function mutation, thought to arise from a steric clash, prompting a His104 residue to enhance DNA binding 38 . Such examples of diverse phenotypes arising from mutations in differing exons of the same gene are well recognised, e.g. differing mutations in FBN1 (Fibrillin 1) can cause Marfan syndrome (with associated tall stature) (OMIM#154700), acromicric dysplasias (with short stature) (OMIM#102370), or stiff skin syndrome (OMIM#184900) [39] [40] [41] . Similarly mutations in PIGN (Phosphatidylinositol Glycan Anchor Biosynthesis Class N) are associated with multiple congenital anomalies-hypotonia-seizures syndrome 1 (OMIM#614080) 42 and Fryns syndrome (congenital diaphragmatic hernia and other dysmorphic features) (OMIM#229850) 43 .
We are only aware of one other skeletal dysplasia reported in association with an inhibitory SMAD (which include SMAD6 and SMAD7). A rare SMAD6 mutation has been associated with susceptibility to non-syndromic midline craniosynostosis 7 (OMIM#617439) -but only in the context of coinheritance of a common variant in BMP2 strongly associated with this condition, a rare example of two locus inheritance 44 . Interestingly, amongst the 1103 conditionally independent SNPs reaching genome-wide significance in the UK-Biobank eBMD GWAS (population n=426,824), as well as identifying the SMAD9 locus, four novel SNPs annotating to SMAD7 were also reported (in addition to three established SNPs associated with SMAD3), all suggesting variation in inhibitory SMADs is likely of functional importance in human biology 18 .
The phenotype we describe here contrasts with that of activating mutations of the BMP receptor, ACVR1, which increase BMP signalling. However, in contrast to p.Leu22Pro SMAD9 HBM, ACVR1 mutations lead to a fatal condition, Fibrous Ossificans Progressiva (FOP, OMIM#135100) 45 . In FOP, muscle tissue differentiates into bone following trivial injury, resulting in the formation of mature bone at multiple extra-skeletal sites. ACVR1 mutations may produce a more severe phenotype, compared with loss-of-function mutations in SMAD9 reported here, since ACVR1 also activates non-SMAD dependent BMP signalling cascades such as the NF-κB and p38 MAP kinase (p38MAPK) pathways, which are upregulated in FOP ACVR1 R206H monocytes 46 .
In view of the benign phenotype which we observed in p.Leu22Pro SMAD9 carriers, our findings suggest that SMAD9 is worthy of consideration as a drug target for osteoporosis. Our zebrafish studies suggest that Smad9 is expressed in pre-osteoblasts, consistent with the profile of an anabolic target capable of stimulating new bone formation through recruitment of early osteoblast progenitors. Given the pathological consequence of excess BMP activation in FOP, this pathway has not previously been prioritised as a possible target in osteoporosis research, despite the profound bone anabolic potential. Interestingly, phosphorylation of Smad9, as part of the Smad1/5/9 heterotrimer, has been researched in relation to fracture healing and bone regeneration: G-proteincoupled receptor kinase 2-interacting protein-1 (GIT1), a shuttle protein in osteoblasts, has been shown to regulate Smad1/5/9 phosphorylation which then mediates BMP2 regulation of Runx2 expression and thus endochondral bone formation at the site of fracture 47, 48 . Moreover, local BMP administration has been used to promote bone repair following surgery 49 . Based on our findings, it is tempting to speculate that treatments intended to suppress SMAD9 activity might prove useful in treating osteoporosis, fractures, and possibly also sarcopenia.
Our study has limitations. All individuals with p.Leu22Pro SMAD9 HBM were female, which reflects the study design which favoured those with a historical DXA scan who are more likely to be female. Whether findings will be similar in men is unknown, although no sex-gene interaction has been described for the LRP4, LRP5, LRP6, or SOST sclerosing bone dysplasias. In the recent UK-Biobank eBMD GWAS, LD score regression analyses suggested that the genetic architecture influencing male and female eBMD was largely shared but that there were some significant differences between the sexes (rG=0.91, SE=0.012, p<0.001) 18 , consistent with earlier epidemiological studies 50 . The small sample of SMAD9 HBM cases (n=4 with pQCT) limited our ability to robustly evaluate associations statistically. The p.Leu22Pro mutation is a reported SNP with an rsID, indicating this is carried within the general population (e.g. in the UK at estimated 92,428 people might be expected to carry this mutation). This may be the case, given there is no indication that the phenotype affects reproductive fitness, and none of the phenotypic characteristics are deleterious to health; and HBM will not be overt unless a DXA scan is performed. The absence of reported association for rs111748421 in the GWAS catalogue is not surprising given the difficulty of imputing extremely rare variants/ mutations for analysis in GWAS. Our GWAS was based on estimated heel BMD quantified by ultrasound rather than DXA-measured BMD. Estimated heel BMD is not used routinely in clinical practice. However, we have previously demonstrated a strong overlap between genetic loci identified by eBMD GWAS and by DXA-measured BMD GWAS 26 .
Conclusions
We report SMAD9 as a novel HBM-causing gene. The clinical phenotype of p.Leu22Pro SMAD9 HBM has many features in common with that of LRP5 HBM, but lacks the deleterious features which characterise SOST HBM (sclerosteosis). As has been reported for both LRP5 and SOST, we demonstrate that SMAD9 can be disrupted by a single point mutation causing an extreme bone phenotype and perturbed by common variation affecting bone density within the general population. The role of SMAD9 in bone biology is supported by our finding of high levels of Smad9 expression in murine osteocytes, and in skeletal elements of zebrafish larvae. Smad9 is thought to inhibit BMP signalling to reduce osteoblast activity; thus, we hypothesise SMAD9 c.65T>C is a loss-offunction mutation reducing BMP inhibition, ultimately leading to enhanced bone formation. Our findings support SMAD9, and its role within the SMAD9-dependent BMP signalling pathway, as a potential novel anabolic target for osteoporosis therapeutics which warrants further investigation.
Methods
The UK HBM Cohort
The HBM study is a UK-based multi-centred observational study of adults with unexplained HBM, identified incidentally on routine clinical DXA scanning. Full details of DXA database screening and participant recruitment have previously been reported 10 . In brief, DXA databases containing 335,115 DXA scans were initially searched for a BMD T or Z-score ≥+4 at any site within the LS or hip, at 13 UK centers. All 1505 DXA images were visually inspected; 962 cases with established and/or artefactual causes of raised BMD were excluded (including exclusion of artefact from LS osteoarthritis (see Supplementary Methods 1 ). As a generalized HBM trait should affect both spine and hip BMD, though not necessarily equally, HBM was defined as a) L1 Z-score of ≥ +3.2 plus TH Z-score of ≥ +1.2 and/or b) TH Z-score ≥ +3.2 plus L1 Z-score of ≥ +1.2 (using age and gender-adjusted BMD Z-scores). A threshold of +3.2 was in keeping with the only published precedent for identifying HBM using DXA 7 . Z rather than T-score was used to limit age bias.
Recruitment 533 unexplained HBM index cases were invited to participate. 248 (47%) were recruited 10 . Index cases were asked to pass on study invitations to their first-degree relatives and spouse/partner(s). These relatives and spouses were invited only once, and non-responders were not followed-up. Relatives/spouses with HBM were in turn asked to pass on study invitations to their (previously uninvited) first-degree relatives and spouses. 893 relatives were invited to participate, of whom 236 (26.4%) were recruited. 217 spouses/ partners were invited to participate, of whom 61 (28.1%) were recruited; 2 individuals invited 2 partners 10 . All participants were clinically assessed using a standardised structured history and examination data collection tool.
DXA measurements
Participants underwent DXA scanning (repeat in the case of index cases) using either GE Lunar Prodigy DXA (software version 13.2, GEHealthcare, Madison, WI, USA) or Hologic Discovery/W DXA (software version Apex 3.0, Hologic Inc. Bedford, MA, USA). Scans were acquired and analysed according to each manufacturer's standard scanning and positioning protocols as previously described 51 . Total Body (TB) bone mineral content (BMC) and density (BMD), Fat Mass (FM) and Lean Mass (LM) were measured, together with L1 and total hip BMD. All DXA images were reviewed for quality control purposes.
Peripheral Quantitative Computed Tomography (pQCT)
pQCT scans were performed at the distal and mid-shaft of the tibia (4, 14, 38 & 66% from the distal endplate) in the non-dominant lower limb using a Stratec XCT2000L (Stratec Medizintechnik, Pforzheim, Germany); voxel size 0.5 mm, CT speed 30 mm/second, XCT software version 5.50d; as published previously 17 . In brief, a reference line at the distal endplate was determined from initial frontal scout view. Cortical bone was defined using a threshold above 650mg/cm 3 (optimal for bone geometry 52 ). Trabecular bone was identified by elimination of cortical bone and therefore trabecular bone mineral density (tBMD) was defined as a density <650mg/cm 3 . Cortical thickness, periosteal circumference and endosteal circumference were derived using a circular ring model. 53 . Twenty population controls were scanned twice on the same day after repositioning; measurement precision (CV) was typically 1 to 3 % [11] . Stratec pQCT machines were calibrated using a COMAC phantom; mean (SD) difference between scanners was 1.18 (0.82) %.
Blood testing including bone turnover markers and DNA extraction
Two non-fasted EDTA samples were collected and serum separated and frozen within 4 hours to -80°C. Bone formation (Procollagen type 1 amino-terminal propeptide [P1NP], total osteocalcin) and resorption (β-C-telopeptides of type I collagen [βCTX]) markers were measured by Electrochemiluminescence immunoassays (ECLIA) performed on the COBAS e601 analyser (Roche Diagnostics, Burgess Hill, UK). Inter-assay coefficient of variation (CV) for P1NP was <3.0% across the range between 5-1200 µg/L; osteocalcin was <5.0% across the range between 0.5-300 µg/L; βCTX was <3.0% across the range between 0.01-6 µg/L. Sclerostin was measured using an enzyme-linked immunosorbent assay (ELISA) kit BI-20492 (Biomedica GmbH, Vienna, Austria) with assay CV of <9.0% across the range 2.6-240 pmol/L. DNA was extracted from peripheral venous blood using standard phenol/ chloroform extraction.
Exclusion of known monogenic causes of HBM
Sanger sequencing of all HBM index cases for exons 2, 3 and 4 of LRP5, SOST (including the van Buchem disease deletion) and LRP4 (exons 25 and 26) excluded seven with LRP5 mutations and one with a SOST mutation 9 , leaving 240 unexplained HBM individuals.
Ethics approval
Written informed consent was collected for all participants in line with the Declaration of Helsinki 54 . This study was approved by the Bath Multi-centre Research Ethics Committee (REC: 05/Q2001/78) and at each NHS Local REC.
Anglo-Australasian Osteoporosis Genetics Consortium (AOGC) HBM and LBM cases
The original AOGC extreme truncate population included 1128 Australian, 74 New Zealand and 753 British women, aged between 55-85 years, five or more years postmenopausal, with either HBM (age and gender-adjusted BMD Z-scores of +1.5 to +4.0, n=1055) or LBM (age-and gender-adjusted BMD Z-scores of -4.0 to -1.5, n=900) 55 . LBM cases were excluded if they had secondary causes of osteoporosis (as previously described 55 ). Unrelated samples of Caucasian ancestry with complete height and weight data and enough high-quality genomic DNA were available in 947 AOGC individuals (426 AOGC high and 521 AOGC low BMD), from which (due to computation capacity limiting sample size) the most extreme HBM cases were then selected, using a threshold TH or LS Zscore ≥+2.5, and the most extreme LBM cases using a LS Z-Score ≤-0.5, so 126 HBM and 493 LBM samples were chosen to undergo WES.
Ethics approval
The AOGC study was approved by the Queensland Office of Human Research Ethics Committee (Ref:2008/018), the University of Queensland (Ref:200800376) and/or relevant research ethics authorities at each participating centre. Directly recruited participants gave written, informed consent. Some participants were recruited through genetic and/or clinical studies (all with appropriate ethical approval) but also provided written informed consent to contribute to collaborative genetic studies [56] [57] [58] . DNA was obtained from peripheral venous blood or from saliva through standard methods.
Whole exome sequencing
Sequencing libraries for 859 samples (240 UK HBM, 126 AOGC HBM, 493 AOGC LBM) were constructed in two batches, determined by sample availability, the first (85 HBM, 619 AOGC) using the Illumina TruSeqDNA sample preparation kit, combined in pools of six for target capture by the Illumina TruSeq Exome v2.0 Enrichment Kit (64Mb capture) and assessed pre and post-capture for quality and yield with the Agilent High Sensitivity DNA assay and KAPA Library Quantification Kit. For the second batch (155 HBM), exome capture was performed using the Nextera® Rapid Capture Exome Enrichment Kit (Cat No FC-140-1003) (62Mb capture) (Illumina, San Diego, California, USA) as per the Nextera® Rapid Capture Enrichment. In both cases massive parallel sequencing was performed with six samples per flow cell lane on the Illumina HiSeq2000 platform and version 2 SBS reagents to generate 100 bp paired-end reads. Base calling, sequence alignment and variant calling were all performed as previously described 59 , in brief, after demultiplexing, the Illumina Data Analysis Pipeline software (CASAVA v.1.8.2) was used for initial base calling. Sequence data were aligned to the current build of the human genome (UCSC Genome Browser, hg19, released February 2009) via the Novoalign alignment tool (v.2.08.02 1) 60 ; sequence alignment files were converted by SAMtools (v.0.1.14) 61 and Picard tools (v.1.42). SNPs and indels were called with the Genome Analysis Toolkit (GATK v.5506) 62, 63 and annotated by ANNOVAR 64 . Further analysis of sequence data was performed with custom scripts employing R and Bioconductor. Good-quality SNPs, excluding all those with a genotype quality score, determined by the GATK algorithm, <60 (range 0 [poor] to 100 [excellent]), were retained. Platform related artefacts variants were identified as variants where the allele count was 6 SDs higher than that expected from the maximum population MAF under the binomial approximation. Remaining SNPs and indels were assessed according to prediction of potentially damaging consequence (''nonsynonymous SNV,'' ''splicing,'' ''frameshift substitution,'' ''stopgain SNV,'' ''stoploss SNV'') by using both RefSeq and UCSC transcripts. Further filtering excluded SNPs with a minor allele frequency (MAF) <0.05 (observed in NCBI dbSNP (GRCh37/ Hg19), 1000 Genomes 65 , ExAC (http://exac.broadinstitute.org/), or internal databases from >3000 exomes), 1000 Genomes small indels (called with the DINDEL program 66 ). Variants not present in any of these databases were considered novel. Platform related artefacts were identified as variants where the allele count was 6 standard deviation higher than that expected from the maximum population MAF under the binomial approximation. Genotype Quality scores for the two additional isolated HBM cases were 99 and read depths were 15,14 and 21,19.
Filtering pipeline applied to unexplained HBM pedigrees
After quality-filtering as described above, data were analyzed for carriage of at least one rare (either novel or maximum population based MAF <0.005) nonsynonymous SNV or indel in a highly conserved region (GERP score <1.5) of a gene, carried by the affected individuals and not carried by unaffected individuals (i.e. autosomal dominant carriage model). Data were then filtered based on functional prediction of SNVs using Polyphen 13 to identify 'probably damaging' and SIFT 12 'deleterious' SNVs. Compound heterozygous and homozygous inheritance were also assessed.
Sanger sequencing validation of pedigree based HBM mutation
Polymerase chain reaction (PCR) amplification of identified exons was performed on 50ng genomic DNA in a reaction mix consisting; 10X Immolase reaction buffer, 10mM dNTPs, 50mM MgCl2, 5µM each primer, 0.5 U Immolase polymerase Taq (Bioline Reagents Ltd, London), and water to final volume of 25µl. PCR cycling conditions and primer sequences are shown in (Supplementary Methods 2). Samples were Sanger sequenced using standard techniques (BigDye v3.1 chemistry, Life Technologies Corporation, California), and capillary sequenced (3130 Genetic Analyzer, Life Technologies Corporation, California). Electropherograms were aligned and analysed using sequence analysis software Genalys (Version 2.0 ß, Masazumi Takahashi).
Multi-marker Analysis of GenoMic Annotation (MAGMA) in UK Biobank
Gene-based tests of association were performed on 362,924 unrelated white British subjects (54% female, GCTA-GRM derived pairwise relatedness < 0.10) from the UK Biobank study that had valid quantitative ultrasound derived heel eBMD and high quality genome-wide HRC and 1000G/UK10K imputed data from the January 2018 release [i.e. 20,490,436 genetic variants with an information quality score > 0.3, MAF > 0.05, minor allele count > 5, genotyping hard call rate > 0.95, and weak evidence of deviation from Hardy-Weinberg equilibrium (p >1x10 -6 )]. A detailed description of the methodology used to generate this resource is published elsewhere 18 . Gene-based tests of association were implemented in MAGMA v1.06 67 using a multi-model approach that combines the association results from three separate gene analysis models: principal components regression, SNP-wise Mean χ2 model [i.e. test statistic derived as the sum of -log(SNP p-value)] and SNP-wise Top χ2 model [(test statistic derived as the sum of -log(SNP p-value) for top SNPs)] to produce an aggregate p-value corresponding to the strength of evidence of association between each of the 19,361 protein coding genes (+/-20kb) and BMD, adjusting for age, sex, genotyping array, assessment centre and ancestry informative principal components 1 -20. Summary results statistics for all genes within +/-800kb of SMAD9 and CHNR1 were looked up. Regional association plots were generated using LocusZoom (v1.3) 68 in conjunction with summary association results from Morris et al 2018 18 .
Gene expression in murine osteocytes
Whole transcriptome sequencing data from the primary osteocytes of four different bone types (tibia, femur, humerus and calvaria) from mice (marrow removed, n=8 per bone) were analysed. A threshold of expression was determined based on the distribution of normalised gene expression for each sample 69 . "Expressed" genes were above this threshold for all 8 of 8 replicates in any bone type. Osteocyte enriched expression of these genes in the skeleton was determined by comparing transcriptome-sequencing data from bone-samples with osteocytes isolated versus those samples with marrow left intact (n=5 per group) 21 .
Replication in high BMD populations
WES data from AOGC were analysed to identify any individual who carried the same rare (MAF <0.025) mutation as identified from analysis of the HBM pedigree. Polyphen 13 and SIFT 12 , PMut 15 and MutationTaster 14 were used for in silico functional prediction. When the same point mutation was identified in more than one individual, haplotypes were compared between index case samples genotyped using an Infinium OmniExpress-12v1.0 GWAS chip read using an Illumina iScan (San Diego, California, USA), with genotype clustering performed using Illumina BeadStudio software.
Protein structural modelling
The amino-acid sequence of human SMAD9 was passed to the HHPred server (https://toolkit.tuebingen.mpg.de/#/tools/hhpred) 70 . This located the best template structures in the Protein Databank for the MH1 domain, 5X6G (mouse SMAD5; 92% identity), and the MH2 domain, 3GMJ (Drosophila melanogaster MAD; 75% identity). Modeller was used to build the domain models according to the HHPred alignments 71 . Chimera was used to introduce point mutations and remodel the domain swapping in the SMAD9-MH1 model 72 .
Zebrafish studies
BMPre:GFP (Tg(5xBMPRE-Xla.Id3:GFP)) 73 and sp7:GFP (Tg(Ola.sp7:NLS-GFP)) 74 transgenic fish (in London AB background) were maintained in standard conditions 75 . Experiments were approved by the University of Bristol Animal Welfare and Ethical Review Body (AWERB) and performed in accordance with a UK Home Office project license. Developmentally staged larvae (following euthanisation in MS222) were fixed in 4% paraformaldehyde (1 hour), dehydrated to 100% methanol and stored at -20°C prior to staining. Immunolabelling protocol was as previously described 76 . Primary antibodies: anti-Smad9 (rabbit polyclonal, Abcam, ab96698) used at a 1/100 dilution and anti-GFP (chicken polyclonal, Abcam, ab13970) used at a 1/200 dilution in blocking buffer (5% horse serum). Secondary antibodies were used (A21206 and A11041, Invitrogen) in a 1/400 dilution and samples were incubated with DAPI (Sigma-Aldrich, 1/1000 dilution) to visualise nuclei. Samples were mounted in 1% low melting point agarose and images were taken with a confocal laser scanning microscope (Leica, SP5II AOBS attached to a Leica DM I6000 inverted epifluorescence microscope) using a 40X PL APO CS (1.3 numerical aperture) lens. Images were processed and colour balanced in Fiji 77 .
Supplementary Information is available in the online version of this paper. 
